Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan

Corrigendum to “Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan” [Lung Cancer, 129 (March) (2019) 55–62]

Lung Cancer ◽

10.1016/j.lungcan.2019.04.010 ◽

2019 ◽

Vol 132 ◽

pp. 157-158

Author(s):

Satoshi Watanabe ◽

Hiroshige Yoshioka ◽

Hiroshi Sakai ◽

Katsuyuki Hotta ◽

Mitsuhiro Takenoyama ◽

...

Keyword(s):

Lung Cancer ◽

Stage Iv ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Multicenter Phase ◽

Phase 1B ◽

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00021-2 ◽

2015 ◽

Vol 16 (7) ◽

pp. 763-774 ◽

Cited By ~ 252

Author(s):

Nick Thatcher ◽

Fred R Hirsch ◽

Alexander V Luft ◽

Aleksandra Szczesna ◽

Tudor E Ciuleanu ◽

...

Keyword(s):

Stage Iv ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Therapy ◽

Line Therapy ◽

Randomised Controlled ◽

Abstract C122: A randomized, multicenter, open-label, phase 2 study of paclitaxel-carboplatin (PC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus PC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)

10.1158/1535-7163.targ-15-c122 ◽

2015 ◽

Author(s):

David Spigel ◽

Alexander Luft ◽

Rodryg Ramlau ◽

Mazen Khalil ◽

Joo-Hang Kim ◽

...

Keyword(s):

Stage Iv ◽

Small Cell ◽

Line Treatment ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE)

Oncology Research and Treatment ◽

10.1159/000448085 ◽

2016 ◽

Vol 39 (9) ◽

pp. 539-547 ◽

Cited By ~ 7

Author(s):

Martin Reck ◽

Michael Thomas ◽

Cornelia Kropf-Sanchen ◽

Jörg Mezger ◽

Mark A. Socinski ◽

...

Keyword(s):

Stage Iv ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Randomized Controlled ◽

First Line Therapy ◽

Line Therapy ◽

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

Annals of Oncology ◽

10.1093/annonc/mds213 ◽

2013 ◽

Vol 24 (1) ◽

pp. 75-83 ◽

Cited By ~ 338

Author(s):

M. Reck ◽

I. Bondarenko ◽

A. Luft ◽

P. Serwatowski ◽

F. Barlesi ◽

...

Keyword(s):

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Extensive Disease ◽

Double Blind ◽

First Line Therapy ◽

Phase 2 Trial ◽

Multicenter Phase ◽

Line Therapy

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70461-9 ◽

2014 ◽

Vol 15 (13) ◽

pp. 1433-1441 ◽

Cited By ~ 72

Author(s):

Pasi A Jänne ◽

Sai-Hong I Ou ◽

Dong-Wan Kim ◽

Geoffrey R Oxnard ◽

Renato Martins ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

A randomized, double-blind, multicenter phase 2 trial of denosumab in combination with chemotherapy as first-line treatment of metastatic non-small cell lung cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps8130 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS8130-TPS8130

Author(s):

David R. Spigel ◽

Fred R. Hirsch ◽

Richard H. De Boer ◽

Ronald B. Natale ◽

Jeffrey Crawford ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Double Blind ◽

Phase 2 Trial ◽

Multicenter Phase ◽

Faculty Opinions recommendation of Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717954646.793472077 ◽

2013 ◽

Author(s):

Nico van Zandwijk

Keyword(s):

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Extensive Disease ◽

Double Blind ◽

First Line Therapy ◽

Phase 2 Trial ◽

Multicenter Phase ◽

Line Therapy

A single-arm, open-label, phase 2 study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer (NSCLC)

Annals of Oncology ◽

10.1093/annonc/mdw383.98 ◽

2016 ◽

Vol 27 ◽

pp. vi454 ◽

Cited By ~ 1

Author(s):

M. Socinski ◽

M. Gil ◽

J. Shahidi ◽

G.Y. Chao ◽

L. Villaruz

Keyword(s):

Stage Iv ◽

Small Cell ◽

Line Treatment ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial

Cancer ◽

10.1002/cncr.29893 ◽

2016 ◽

Vol 122 (7) ◽

pp. 1050-1059 ◽

Cited By ~ 23

Author(s):

Masayuki Takeda ◽

Takeharu Yamanaka ◽

Takashi Seto ◽

Hidetoshi Hayashi ◽

Koichi Azuma ◽

...

Keyword(s):

Small Cell ◽

Line Treatment ◽

Phase 2 ◽

Oncology Group ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Randomized Phase 2 ◽